MYH11 inhibitors belong to a distinct chemical class that is characterized by their ability to modulate the activity of the MYH11 gene product. The MYH11 gene encodes for the smooth muscle myosin heavy chain protein (SM-MHC), which is a key component of the contractile machinery in smooth muscle cells. These inhibitors are designed to target the enzymatic or structural functions of SM-MHC, thereby influencing its role in mediating smooth muscle contraction. The SM-MHC protein is crucial for the regulation of various physiological processes, including blood vessel tone, gastrointestinal motility, and airway constriction. MYH11 inhibitors typically work by interfering with the ATPase activity of SM-MHC, which is essential for energy generation during the contraction-relaxation cycle. By modulating this enzymatic activity, MYH11 inhibitors can lead to changes in the force and velocity of smooth muscle contractions.
Structurally, MYH11 inhibitors often possess functional groups that enable them to interact with specific binding sites on SM-MHC, thereby disrupting its normal function. These inhibitors may act competitively or non-competitively with ATP, affecting the phosphorylation and dephosphorylation of the protein. Some MYH11 inhibitors may target the actin-binding domain of SM-MHC, impeding its interaction with actin filaments and consequently diminishing the contractile force generated by smooth muscle cells. The design and development of MYH11 inhibitors require a deep understanding of the structural and functional characteristics of SM-MHC, as well as an awareness of the downstream effects of altering smooth muscle contraction. Consequently, research in this field involves a multidisciplinary approach that combines structural biology, medicinal chemistry, and pharmacology to design compounds with high specificity and potency for SM-MHC inhibition. Despite the complexities associated with the development of these inhibitors, they offer a promising avenue for the modulation of smooth muscle function, with implications for various physiological and pathophysiological processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
A small molecule inhibitor that interferes with myosin and actin filament interaction, thereby hindering muscle contraction. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
This compound selectively inhibits Rho-associated protein kinases (ROCK), indirectly leading to MYH11 inhibition and relaxation of smooth muscles. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $112.00 $449.00 $673.00 $1224.00 | 2 | |
An inhibitor of myosin light chain kinase (MLCK), it reduces the phosphorylation of the myosin light chain, resulting in decreased muscle contraction. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
A calcium channel blocker that limits calcium entry into smooth muscle cells, indirectly inhibiting MYH11 and inducing muscle relaxation. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Similar to nifedipine, it's a calcium channel blocker that indirectly inhibits MYH11 by reducing calcium levels within smooth muscle cells. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
Another myosin light chain kinase (MLCK) inhibitor that, like ML-9, impedes MYH11-mediated muscle contraction. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $74.00 $166.00 | 2 | |
A calcium channel blocker that restricts calcium influx into smooth muscle cells, resulting in MYH11 inhibition and muscle relaxation. | ||||||